Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EC Ratifies Blood Pressure Monitor Decision, Calls For Treatment Guidelines

This article was originally published in The Gray Sheet

Executive Summary

Consensus guidelines indicating patient populations likely to benefit from the use of ambulatory blood pressure monitors (ABPMs) need to be developed before CMS issues a coverage decision for the devices, according to the executive committee (EC) of the agency's Medicare Coverage Advisory Committee

You may also be interested in...

MCAC EC Channels Spirit Of PET Imaging Panel By Altering Recommendation

The Centers for Medicare and Medicaid Services' Medicare Coverage Advisory Committee Executive Committee took the unusual step during an Oct. 16 meeting of altering a recommendation from its Diagnostic Imaging Panel regarding positron emission tomography (PET) prior to ratifying it for CMS consideration.

QUOTED. 4 December. Eric Borin.

Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts